Alberta Enterprise Corporation invested additional $5 million to benefit Alberta startups
On Oct. 19, 2020, Alberta Enterprise announced that it had invested an additional $5 million into its third…
Mateon’s phase 2 global study for OT-101/ TGF- Inhibitor against COVID-19 cleared for patient enrollment in Argentina
On Oct. 19, 2020, Mateon Therapeutics announced the receipt of approval from Republica Argentina Poder Ejecutivo Nacional, the…
RNA ‘ticker tape’ records gene activity over time
On Oct. 19, 2020, researchers at MIT, Harvard, and the Broad Institute of MIT announced they had developed…
BARDA reselected ICON as preferred partner to help strengthen U.S. emergency preparedness and response
On Oct. 19, 2020, ICON announced that it had been re-selected by the Biomedical Advanced Research and Development…
Just – Evotec Biologics received grant to enable an antibody product for the prevention of COVID-19
On Oct. 19, 2020, Evotec announced that its Seattle-based subsidiary, Just – Evotec Biologics had received a grant…
Solidarity Therapeutics trial produced conclusive evidence on effectiveness of repurposed drugs for COVID-19
On Oct. 15, 2020, the World Health Organization (WHO) announced Interim that results from the Solidarity Therapeutics Trial,…
Fred Hutch completed move-in of Lake Union Steam Plant
On Nov. 9, 2020, after more than two years of reconstruction efforts, scientists from the Fred Hutchinson Cancer…
FDA approved first treatment for Ebola virus
On Oct. 14, 2020, the FDA approved Regeneron Pharmaceutical’s Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three…
Regeneron’s antibody cocktail REGN-EB3 (Inmazeb) first FDA-approved treatment for Ebola (Zaire Ebolavirus)
On Oct. 14, 2020, Regeneron announced that the FDA had approved Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn) for the…
Mosquitoes’ taste for blood traced to four types of neurons
On Oct. 13, 2020, Howard Hughes Medical Institute Investigator Leslie Vosshall’s team at The Rockefeller University and colleagues…
NIH launched its ACTIV-5 ‘Big Effect Trial’ evaluating Humanigen’s Lenzilumabas potential COVID-19 therapy
On Oct. 13, 2020, Humanigen announced that the National Institute of Allergy and Infectious Diseases (NIAID), had launched…
RedHill Biopharma announced partnerships to expand manufacturing for COVID-19 therapeutic candidate opaganib
On Oct. 13, 2020, RedHill Biopharma announced collaborations with two specialist pharmaceutical manufacturers in Europe and Canada to…
Relation between COVID-19 and Guillain-Barre syndrome in adults: a systematic review published
On Oct. 8, 2020, the relation between COVID-19 and Guillain-Barre syndrome in adults: a systematic review was published…
Biotechnology | COVID-19 | Disease | Life Science News | Medicine | NIH | Therapeutics
La Jolla Institute for Immunology awarded $1.4 million to study COVID-19 in Latino Americans
On Oct. 8, 2020, the La Jolla Institute for Immunology (LJI) announced it had been granted $1.4 million…
Lilly announced supply of potential COVID-19 antibody therapy for low- and middle-income countries
On Oct. 8, 2020, Eli Lilly and the Bill & Melinda Gates Foundation, as part of the COVID-19…
SIGA announced Public Health Agency of Canada intent to purchase up to 33,300 courses of Oral TPOXX
On Oct. 8, 2020, SIGA Technologies announced that the Public Health Agency of Canada (PHAC) has issued an…
The Nobel Prize in Chemistry for 2020 was awarded to Emmanuelle Charpentier and Jennifer A Doudna
On Oct. 7, 2020, the Nobel Prize in Chemistry 2020 was awarded to Emmanuelle Charpentier and Jennifer Doudna…
RedHill Biopharma’s Opaganib COVID-19 study passed second independent committee review
On Oct. 7, 2020, RedHill Biopharma announced that the U.S. Phase 2 study with opaganib (Yeliva, ABC294640)1 in…
RedHill Biopharma opaganib COVID-19 study passed second independent committee review
On Oct. 7, 2020, RedHill Biopharma announced that the U.S. Phase 2 study with opaganib (Yeliva, ABC294640)1 in…
Sorrento announced discovery of salicyn-30 small molecule that strongly inhibits SARS-CoV-2 infection
On Oct. 7, 2020, Sorrento Therapeutics announced that it had discovered a small molecule termed Salicyn-30 that demonstrated…
Mateon announced first patient enrolled in ARTI-19 multicenter interventional study of Artshield against COVID-19
On Oct. 7, 2020, Mateon Therapeutics announced the first patient enrolled this week in its Phase IV study…
NIH RADx initiative advanced six new COVID-19 testing technologies
On Oct. 6, 2020, the National Institutes of Health (NIH), working in collaboration with the Biomedical Advanced Research…
Hologic Panther Platform and HIV-1 Quant assay used in ‘HIV Cure’ research
On Oct. 6, 2020, Hologic announced that two studies in the Journal of Clinical Microbiology demonstrated the utility…
Mateon initiated commercialization of Artshield
On Oct. 5, 2020, Mateon Therapeutics announced that ArtiShieldTM had been approved for manufacture and marketing by the…
Johnson & Johnson completed acquisition of Momenta Pharmaceuticals for $65 billion
On Oct. 1, 2020, Johnson & Johnson announced it had successfully completed its acquisition of Momenta Pharmaceuticals, a…
Sorrento Therapeutics and ViralClear entered agreement to explore combination antibody plus antiviral therapy against COVID-19
On Sept. 30, 2020, ViralClear Pharmaceuticals and Sorrento Therapeutics announced the companies were exploring the synergistic potential of…
Bio-Techne announced opening of GMP manufacturing facility in Twin Cities
On Sept. 30, 2020, Bio-Techne announced the opening of its approximately 61,000 square foot state-of-the-art GMP (Good Manufacturing…
AXIM Biotechnologies filed patent for world’s first face mask designed to capture SARS-CoV-2 COVID-19
On Sept. 29, 2020, AXIM Biotechnologies announced that it had filed a provisional patent for a first-in-class face…
Pascal Biosciences confirmed specific cannabinoids combat Coronavirus
On Sept. 23, 2020, Pascal Biosciences announced the Company had confirmed an earlier report that certain cannabinoids block…
Brazil approved RedHill Biopharma’s phase 2/3 COVID-19 study with opaganib
On Sept. 22, 2020, RedHill Biopharma announced approval from the Brazilian Health Regulatory Agency (ANVISA) for its ongoing…